The following perpetrator compounds were selected:

- **Atazanavir** (UGT1A1 inhibitor), PBPK model v1.0 description and evaluation in
  https://github.com/Open-Systems-Pharmacology/Atazanavir-Model/releases/tag/v1.0 

- **Mefenamic acid** (UGT1A9 inhibitor), PBPK model v1.0 description and evaluation in
 https://github.com/Open-Systems-Pharmacology/Mefenamic-acid-Model/releases/tag/v1.0 

  

The following sensitive substrates as victim drugs were selected:

- **Raltegravir** (UGT1A1 substrate), PBPK model v1.0 description and evaluation in
  https://github.com/Open-Systems-Pharmacology/Raltegravir-Model/releases/tag/v1.0 
  
- **Dapagliflozin** (UGT1A9 substrate), PBPK model v1.0 description and evaluation in
  https://github.com/Open-Systems-Pharmacology/Dapagliflozin-Model/releases/tag/v1.0 
  
  â€‹	

Corresponding DDI modelling files can be found in:

- **Atazanavir-Raltegravir-DDI** (v1.0):
  https://github.com/Open-Systems-Pharmacology/Atazanavir-Raltegravir-DDI/releases/tag/v1.0
- **Mefenamic acid-Dapagliflozin-DDI** (v1.0):
  https://github.com/Open-Systems-Pharmacology/Mefenamic_acid-Dapagliflozin-DDI/releases/tag/v1.0



The following clinical studies are part of this qualification report:

| Enzyme | Perpetrator / victim           | Study design                                                 | Clinical study                      |
| ------ | ------------------------------ | ------------------------------------------------------------ | ----------------------------------- |
| UGT1A1 | Atazanavir / raltegravir       | Raltegravir: 100 mg single dose on day 7 simultaneous with the 7th dose of atazanavir<br />Atazanavir: 400 mg once daily dosing | [Iwamoto 2008](#4-References)       |
| UGT1A1 | Atazanavir / raltegravir       | Raltegravir: 1200 mg single dose on day 7 simultaneous with the 7th dose of atazanavir<br />Atazanavir: 400 mg once daily dosing | [Krishna 2008,](#4-References)      |
| UGT1A1 | Atazanavir / raltegravir       | Raltegravir: 400 mg once daily dosing (control phase 400 mg twice daily)<br />Atazanavir: 400 mg once daily dosing<br />DDI assessment on day 8 | [Neely 2010](#4-References)         |
| UGT1A1 | Atazanavir / raltegravir       | Raltegravir: 400 mg twice daily dosing <br />Atazanavir: 300 mg twice daily dosing<br />DDI assessment on day 27 | [Zhu 2010](#4-References)           |
| UGT1A9 | Mefenamic acid / dapagliflozin | Dapagliflozin: 10 mg single dose on day 2 simultaneous with the 5th dose of mefenamic acid (24 hours after the first mefenamic acid dose)<br />Mefenamic acid: 500 mg loading dose, followed by 8 doses of 250 mg mefenamic acid every 6 hours | [Kasichayanula 2013](#4-References) |

